Depression in Children

Earn CME/CE in your profession:


Continuing Education Activity

Depressive disorders in the Diagnostic and Statistical Manual of Mental Disorders (DSM–5) include diagnoses of different disorders, for example, major depressive disorder (MDD), disruptive mood dysregulation, persistent depressive disorder, and depression not otherwise specified. This activity eviews major depressive disorder (MDD). MDD is the first cause of disability among adolescents aged 10 to 19 years (WHO 2014). Suicide is the third cause of death in this age group, and adolescent depression is a major risk factor for suicide. Depressed adolescents experienced significantly more stressors during the year before onset when compared with a comparable 12-month period in normal controls. This activity reviews the evaluation and management of depression in children and the role of interprofessional team members in collaborating to provide well-coordinated care and enhance patient outcomes.

Objectives:

  • Review the etiology of depression in children.
  • Describe the presentation of depression in children.
  • Summarize the treatment of depression in children.
  • Outline the evaluation and management of depression in children and the role of interprofessional team members in collaborating to provide well-coordinated care and enhance patient outcomes.

Introduction

Depressive disorders in the Diagnostic and Statistical Manual of Mental Disorders (DSM–5) encompasses the diagnoses of major depressive disorder (MDD), disruptive mood dysregulation disorder (DMDD), persistent depressive disorder--dysthymia--(PDD), and depression not otherwise specified. This article reviews major depressive disorder (MDD) in the pediatric population.

MDD is the first cause of disability among adolescents aged 10 to 19 years (WHO 2014). Suicide is the third cause of death in this age group, and adolescent depression is a major risk factor for suicide. Depressed adolescents experienced significantly more stressors during the year before onset when compared with a comparable 12-month period in normal controls.

Etiology

The etiology of depression is multifactorial and complex resulting from interactions between biological vulnerabilities and environmental factors.

Genes and Heritability

A meta-analysis found that heritability is a main risk factor for mental health concerns, including depression, between ages 13 and 35.[1] In twin studies, heritability was found to be around 60% to 70%.

Offspring of depressed parents have an increased risk of 2 to 4 times compared with offspring of healthy parents. Genes-environmental interaction contributes to this risk, specifically by increasing susceptibility to environmental stress.[2] Also, different studies reported that the serotonin transporter gene variant (5-HTTLPR) might increase the risk of depression in the presence of adverse life events or early maltreatment.[3]

Psychosocial Risk Factors

Stressful life events often precede the onset and recurrence of depressive symptoms and episodes in adolescents, especially with girls.[4] However, most children and adolescents who experience such events do not develop depression. Examples of life stressors include events involving loss, maltreatment, romantic break-up, being bullied by peers, and parent-child conflicts.

Cognitive Risk Factors

Depressed adolescents have an attentional bias and a memory bias. They recall more negative and fewer positive words than a non-depressed adolescent.[5] There is a bidirectional relationship between children's low perceived competence and depression. Children’s underestimation of their competence predicts depressive symptoms and vice versa. Previous depression also predicts underestimation of competence.[6][7] Rumination, dwelling excessively, does also predict the onset and continuation of depression.[8]

Other Factors

  • Sleep problems such as shorter rapid eye movement (REM) latency, higher REM density, decreased sleep efficiency, and higher frontal slow-wave activity were associated with the development of depression[9][10]
  • Co-morbid medical illness: Epilepsy, multiple sclerosis, diabetes, and others
  • Other mental illness: Anxiety disorders, obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD)
  • Medications: Corticosteroids, interferons, mefloquine, progestin-releasing implanted contraceptives, and propranolol
  • Substance use: Alcohol

Epidemiology

The pediatric depression annual incidence rate is 1% to 2% at age 13 and from 3% to 7% at age 15.[11] The ratio is equal between males and females during childhood (1:1) and 1:2 during adolescence, respectively. After puberty, the risk of depression increases by a factor of 2 to 4, particularly in females.[12] Different studies reported that lower or middle-income countries have higher rates of depression in adolescents compared to higher-income countries (10% to 13% in boys and 12% to 18% for girls).[13][14] 

History and Physical

DSM–5 criteria for diagnosing depression in the pediatric population:

  • The presence of at least 5 of the following items in the same 2-week period with having a change in the level of function. At least 1 of the items is either a depressed mood or loss of interest or pleasure. It is important to note that other medical conditions can not explain symptoms.
    • Depressed or irritable mood most of the day, almost every day, as demonstrated by either subjective report, for example, the patient feels sad, empty, or hopeless, or observation made by others, for example, the patient appears sad. 
    • A significant decrease in interest or pleasure in activities most of the day, nearly every day as indicated by self-reporting or observation
    • Failure to make expected weight gain or remarkable weight loss when not dieting or a remarkable weight gain, or decrease or increase in daily appetite
    • Lack of sleep or excessive sleeping almost every day
    • Psychomotor unrest or retardation almost every day (observable by others, not merely subjective feelings of restlessness).
    • Lack of energy nearly every day
    • Feelings of worthlessness or inappropriate guilt (possibly delusional) nearly every day (not merely self-reported or guilt for being sick)
    • Decrease capacity to think or concentrate or indecisiveness, almost every day (either by self-report or as observed by others)
    • Repeated thoughts of death (not just fear of dying), recurrent suicidal ideation without specific plans; suicide attempt; or a definite plan to commit suicide
  • The illness causes clinically remarkable distress or impairment in social, occupational, or other important areas of functioning.

  • The episode is not due to the physiological effects of a substance or another medical condition

  • The occurrence of the major depressive episode cannot be explained by schizoaffective disorder, schizophrenia, schizophreniform disorder, delusional disorder, or other specified and unspecified schizophrenia spectrum and other psychotic disorders

  •  Had no manic or hypomanic episodes

Evaluation

The USPSTF (US Preventive Services Task Force) recommends screening for a major depressive disorder (MDD) in adolescents aged 12 to 18 years.[15] Some screening questionaries are available to screen for depression in primary settings. Examples are:

  1. PHQ9: The 9-item Patient Health Questionnaire, scores each of the nine DSM criteria as "0" (not at all) to "3" (nearly every day), providing a 0 to 27 severity score
  2. The Zung Self-Rating Depression Scale: A 20-item self-report questionnaire.
  3. The Beck Depression Inventory-II (BDI-II): 21-item self-report inventory

There is no specific blood test or imaging that can be done to diagnose depression. However, the evaluation of depression needs to include some investigations to rule out some of the differential diagnoses. Examples are:

  • Complete blood count (CBC) and vitamin B-12 levels
  • Electrolytes including magnesium, calcium, and phosphate.
  • TSH, T3, free T4
  • Liver function tests, renal function test (blood urea nitrogen, creatinine)

Other investigations should be ordered whenever other medical illnesses are suspected, for example, urine toxicology screen, blood alcohol level, HIV test, dexamethasone suppression test, and an ACTH stimulation test.

Treatment / Management

Treatment should aim for recovery, achieving full remission of symptoms, and returning to the premorbid level of functioning. Biopsychosocial treatment plans for children and adolescent is similar to adults' plans. However, in children and adolescents, clinicians often start with psychosocial interventions.

Psychosocial Interventions Involving the Child and Parents

Psychosocial interventions are the first-line treatment in case of mild-to-moderate depression.

  1. Psycho-education including education about the illness, the importance of having a good sleep, and good nutrition
  2. Exercising for at least 30 minutes a day
  3. Cognitive and behavioral therapy to help the depressed individual identify cognitive distortions and to learn cognitive restructuring skills, problem-solving skills, and to use behavioral activation techniques
  4. Interpersonal therapy aimed to decrease interpersonal conflicts by helping depressed individual learning interpersonal problem-solving skills and changing dysfunctional communication and relational patterns
  5. Family therapy: Different family therapy modules could be of help to the depressed individual and family.

Medication

Different studies had shown that antidepressant efficacy is different between adults and children. The placebo effect is stronger among children and adolescents compared to adults, especially with mild-moderate depression.

It is important to discuss the effects and side-effects with the patient and parents. Typically, for the first month after prescribing an antidepressant follow-up should be weekly. This allows for close monitoring of side effects as well as supportive management.

Antidepressants that are most commonly used in this age group are fluoxetine, sertraline, citalopram, and escitalopram. Fluoxetine and escitalopram are approved by the FDA for adolescent depression. Venlafaxine, a serotonin-norepinephrine repute inhibitor (SNRI), is a second-line drug due to its side effects.

Side Effects

One of the major side effects of antidepressants is an increase in suicidal thoughts, but not suicidal attempts. Thus, monitoring suicidal risk is required. Other side effects include gastrointestinal problems, agitation, nightmares and sleep disturbance, weight gain, and sexual dysfunction.

Management of Comorbid Disorders

Clinicians should monitor comorbid disorders such as sleep disorders, anxiety disorders, and other underlying medical causes of depression.

Differential Diagnosis

Bipolar Depression

To diagnose a bipolar affective disorder, clinicians need to document one manic or hypomanic episode. The challenge with the pediatric population is that bipolar disorders often start with an episode of depression in childhood or adolescence.

Adjustment Disorder

The onset of symptoms in adjustment disorder occurs following a significant life event.

Substance Use Disorders

Either withdrawal from substances, for example, amphetamines or cocaine, or intoxication (alcohol) could present a clinical picture similar to depression. Depression could be diagnosed as a concurrent disorder if depressive symptoms persist or precede the onset of substance use.

Medical Conditions

Different medical conditions could present with depression, for example, multiple sclerosis, stroke, or hypothyroidism.

Attention-Deficit Hyperactivity Disorder

Attention-deficit hyperactivity disorder (ADHD) could present with irritable mood, poor concentration, and these symptoms are similar to pediatric depression symptoms.

Prognosis

The most important factor in predicting the severity and improvement percentage of depression is the duration of untreated depression. Active treatment decreases the depressive episode duration.[16] The remission rate depends on different factors like disorder severity, with rates among people with severe disorders being 20% to 30% lower than mild-to-moderate depression. Around, 60 % to 90% of mild-to-moderate depressive episodes in adolescents remit within a year. However, recurrence within 5 years occurs in around 50 % to 70%. Patients with major depression from specialist psychiatry settings have had long-term recurrence rates of between 50% and 64%.[17] The relapse rate is higher when the remission from depression is partial (67.6%) compared to when it is complete remission (15.18%).[18] Children and adolescents who develop a recurrent or chronic disorder extending into adulthood are more likely to suffer considerable disability and impairment.[19]

Enhancing Healthcare Team Outcomes

Major depressive disorder in the pediatric population is a treatable condition. However, it is mostly underdiagnosed and under-treated. The goal of treatment should be to minimize the impact of depression on the child's functioning at home, school, and on social/peer relationships while aiming for a full recovery. This would be better obtained via outpatient treatment with an interprofessional team consisting of a mental health nurse, a psychiatrist, a pediatrician, a psychotherapist, and a case manager. Admission to the inpatient unit should be considered when the depression is severe, or the child's safety cannot be guaranteed. Pediatricians and mental health professionals should always promote and advocate for this population's mental health, increase awareness and aim for decreasing the stigma.[20]


Details

Author

Ali J. Alsaad

Author

Yusra Azhar

Updated:

4/24/2023 12:37:58 PM

References


[1]

Bergen SE, Gardner CO, Kendler KS. Age-related changes in heritability of behavioral phenotypes over adolescence and young adulthood: a meta-analysis. Twin research and human genetics : the official journal of the International Society for Twin Studies. 2007 Jun:10(3):423-33     [PubMed PMID: 17564500]

Level 1 (high-level) evidence

[2]

Thapar A, Collishaw S, Pine DS, Thapar AK. Depression in adolescence. Lancet (London, England). 2012 Mar 17:379(9820):1056-67. doi: 10.1016/S0140-6736(11)60871-4. Epub 2012 Feb 2     [PubMed PMID: 22305766]


[3]

Uher R, McGuffin P. The moderation by the serotonin transporter gene of environmental adversity in the etiology of depression: 2009 update. Molecular psychiatry. 2010 Jan:15(1):18-22. doi: 10.1038/mp.2009.123. Epub     [PubMed PMID: 20029411]


[4]

Patton GC, Coffey C, Posterino M, Carlin JB, Bowes G. Life events and early onset depression: cause or consequence? Psychological medicine. 2003 Oct:33(7):1203-10     [PubMed PMID: 14580075]


[5]

Neshat-Doost HT, Taghavi MR, Moradi AR, Yule W, Dalgleish T. Memory for emotional trait adjectives in clinically depressed youth. Journal of abnormal psychology. 1998 Nov:107(4):642-50     [PubMed PMID: 9830251]


[6]

Hoffman KB, Cole DA, Martin JM, Tram J, Seroczynski AD. Are the discrepancies between self- and others' appraisals of competence predictive or reflective of depressive symptoms in children and adolescents: a longitudinal study, Part II. Journal of abnormal psychology. 2000 Nov:109(4):651-62     [PubMed PMID: 11195989]


[7]

Cole DA. Preliminary support for a competency-based model of depression in children. Journal of abnormal psychology. 1991 May:100(2):181-90     [PubMed PMID: 2040769]


[8]

Oppenheimer CW, Technow J, Hankin BL, Young JF, Abela JR. Rumination and Excessive Reassurance Seeking: Investigation of the Vulnerability Model and Specificity to Depression. International journal of cognitive therapy. 2012 Sep 1:5(3):254-267     [PubMed PMID: 24527172]


[9]

Rao U, Hammen CL, Poland RE. Risk markers for depression in adolescents: sleep and HPA measures. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2009 Jul:34(8):1936-45. doi: 10.1038/npp.2009.27. Epub 2009 Mar 4     [PubMed PMID: 19262465]


[10]

Tesler N, Gerstenberg M, Franscini M, Jenni OG, Walitza S, Huber R. Increased frontal sleep slow wave activity in adolescents with major depression. NeuroImage. Clinical. 2016:10():250-6. doi: 10.1016/j.nicl.2015.10.014. Epub 2015 Nov 10     [PubMed PMID: 26870661]


[11]

Lewinsohn PM, Rohde P, Seeley JR. Major depressive disorder in older adolescents: prevalence, risk factors, and clinical implications. Clinical psychology review. 1998 Nov:18(7):765-94     [PubMed PMID: 9827321]


[12]

Hyde JS, Mezulis AH, Abramson LY. The ABCs of depression: integrating affective, biological, and cognitive models to explain the emergence of the gender difference in depression. Psychological review. 2008 Apr:115(2):291-313. doi: 10.1037/0033-295X.115.2.291. Epub     [PubMed PMID: 18426291]


[13]

Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL. Global Burden of Disease and Risk Factors. 2006:():     [PubMed PMID: 21250374]


[14]

Ruchkin V, Sukhodolsky DG, Vermeiren R, Koposov RA, Schwab-Stone M. Depressive symptoms and associated psychopathology in urban adolescents: a cross-cultural study of three countries. The Journal of nervous and mental disease. 2006 Feb:194(2):106-13     [PubMed PMID: 16477188]


[15]

Siu AL, US Preventive Services Task Force. Screening for Depression in Children and Adolescents: US Preventive Services Task Force Recommendation Statement. Pediatrics. 2016 Mar:137(3):e20154467. doi: 10.1542/peds.2015-4467. Epub 2016 Feb 8     [PubMed PMID: 26908686]


[16]

Hung CI, Liu CY, Yang CH. Untreated duration predicted the severity of depression at the two-year follow-up point. PloS one. 2017:12(9):e0185119. doi: 10.1371/journal.pone.0185119. Epub 2017 Sep 21     [PubMed PMID: 28934289]


[17]

Patton GC, Coffey C, Romaniuk H, Mackinnon A, Carlin JB, Degenhardt L, Olsson CA, Moran P. The prognosis of common mental disorders in adolescents: a 14-year prospective cohort study. Lancet (London, England). 2014 Apr 19:383(9926):1404-11. doi: 10.1016/S0140-6736(13)62116-9. Epub 2014 Jan 16     [PubMed PMID: 24439298]


[18]

Pintor L, Gastó C, Navarro V, Torres X, Fañanas L. Relapse of major depression after complete and partial remission during a 2-year follow-up. Journal of affective disorders. 2003 Feb:73(3):237-44     [PubMed PMID: 12547292]


[19]

Birmaher B, Ryan ND, Williamson DE, Brent DA, Kaufman J. Childhood and adolescent depression: a review of the past 10 years. Part II. Journal of the American Academy of Child and Adolescent Psychiatry. 1996 Dec:35(12):1575-83     [PubMed PMID: 8973063]


[20]

Birmaher B, Brent D, AACAP Work Group on Quality Issues, Bernet W, Bukstein O, Walter H, Benson RS, Chrisman A, Farchione T, Greenhill L, Hamilton J, Keable H, Kinlan J, Schoettle U, Stock S, Ptakowski KK, Medicus J. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. Journal of the American Academy of Child and Adolescent Psychiatry. 2007 Nov:46(11):1503-26     [PubMed PMID: 18049300]

Level 2 (mid-level) evidence